Oppenheimer
Oppenheimer & Co. Inc. is the New York-based broker-dealer of NYSE-listed Oppenheimer Holdings, combining wealth management with investment banking, trading and equity research. Its analysts rate stocks against the S&P 500 on an Outperform, Perform and Underperform scale.
Activity24M
RatingsPrice targetsKey figures
- Stocks covered
- 50712M
- Actions
- 1,73012M
- Ratings / Price targets
- 910 / 820
- Upgrades / Downgrades
- 41 / 54
- Initiations
- 26
- Buy-rated
- 84%of 426 rated
- Median upside
- +25.3%
- Targets raised / lowered
- 433 / 213
- On record
- Feb 2012 – Sep 2026
Overview
Oppenheimer's equity research rated 670 companies firmwide as of September 2025, about two-thirds of them Outperform. Former Oppenheimer analysts include Meredith Whitney, Henry Blodget and Steve Eisman. The firm presents its equity research as serving retail, institutional and corporate clients alike. As of 2026 its thematic platform is led by research director William Bird.
Oppenheimer traces its lineage to Fahnestock & Co., founded in New York in 1881, and to Oppenheimer & Co., a broker-dealer partnership formed in 1950 and named for Max E. Oppenheimer. CIBC bought Oppenheimer & Co. in 1997; in 2003 Fahnestock Viner Holdings acquired CIBC Oppenheimer's U.S. private-client and asset-management businesses and adopted the Oppenheimer name. In January 2008 it acquired CIBC World Markets' U.S. investment banking and equities businesses. Rob Lowenthal succeeded his father Albert as chief executive in May 2025.
Milestones
- 1881
Fahnestock & Co. founded in New York
- 1950
Oppenheimer & Co. formed as a broker-dealer partnership
- 1997
CIBC acquires Oppenheimer & Co. for $525 million
- 2003
Fahnestock buys CIBC Oppenheimer units, adopts Oppenheimer name
- 2008
Acquires CIBC World Markets' U.S. capital markets businesses
- 2025
Rob Lowenthal succeeds Albert Lowenthal as CEO
Firm facts
- Legal name
- Oppenheimer & Co. Inc.
- Type
- Full-service
- Founded
- 1881
- Headquarters
- New York, United States
- Parent
- Oppenheimer Holdings Inc.
- Listing
- NYSE: OPY
- President and Chief Executive Officer
- Robert S. Lowenthal
- Rating scale
- OutperformPerformUnderperform12-18 months
- Website
- oppenheimer.com
Research philosophy
The mission of Oppenheimer’s Equity Research department is to provide thoughtful, insightful and differentiated research so that our clients can make informed investment decisions.
Oppenheimer emphasizes independent analysis and investment strategies tailored to clients. Its consumer analysts combine field research with proprietary data, while its special-situations team studies spin-offs, restructurings and companies emerging from bankruptcy. As of 2026, its thematic research examines long-term trends that span multiple sectors.
Rating methodology
Since January 2008 analysts have rated stocks Outperform, Perform or Underperform relative to the S&P 500 over the next 12 to 18 months, with price targets set on the same horizon.
Coverage12M
Sectors
Most covered24M
| Stock | Rating | Target |
|---|---|---|
 Alphabet Inc.GOOG | Outperform | $400 |
 Bank of America CorporationBAC | Perform | $61 |
 Netflix, Inc.NFLX | Outperform | $85 |
 U.S. BancorpUSB | Outperform | $73 |
 Amazon.com, Inc.AMZN | Outperform | $320 |
 Citigroup Inc.C | Perform | $145 |
 Marvell Technology, Inc.MRVL | Outperform | $325 |
 Vertiv Holdings CoVRT | Outperform | $325 |
 Salesforce, Inc.CRM | Outperform | $275 |
 Onto Innovation Inc.ONTO | Outperform | $450 |
Most active analysts
- Noah Kaye34 notesVRTCLHORA
- Jay Olson29 notesBIIBPRAXRVMD
- Jason Helfstein26 notesGOOGCOMPCART
- Chris Kotowski25 notesHLNECJEF
- Ian Zaffino24 notesTLNTPBCXT
- Ittai Kidron24 notesTWLOPANWFROG
Recent actions
| Date | Stock | Rating action | Rating | Target | Analyst |
|---|---|---|---|---|---|
| Sep 22 |  Viking Therapeutics, Inc.VKTX | Target | $100 →$120 | ||
| Sep 22 | TYTyra Biosciences, Inc.TYRA | Reiterate | Outperform | $50 →$40 | |
| Sep 22 | CNConnect Biopharma Holdings LimitedCNTB | Reiterate | Outperform | ||
| Sep 22 | KBKBR, Inc.KBR | Target | $60 →$50 | ||
| Sep 22 |  Microsoft CorporationMSFT | Reiterate | Outperform | $515 →$570 | Brian Schwartz |
| Sep 22 |  Coherent, Inc.COHR | Upgrade | Outperform →Buy | ||
| Sep 22 |  Turning Point Brands, Inc.TPB | Reiterate | Outperform | $130 →$90 | Ian Zaffino |
| Sep 21 |  Tesla, Inc.TSLA | Reiterate | Perform | ||
| Sep 21 |  Boston Scientific CorporationBSX | Target | $85 →$65 | Suraj Kalia |